Goldenwell Biotech, Inc. (GWLL)

Market Cap	89.10M +350.0%
Revenue (ttm)	55.00 -60.4%
Net Income	-275.54K
EPS	-0.00
Shares Out	99.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	0.5200
Previous Close	0.5200
Day's Range	0.5200 - 0.9000
52-Week Range	0.3880 - 10.0000
Beta	4.75
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Goldenwell Biotech

Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2019
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: GWLL

Financial Performance

In 2025, Goldenwell Biotech's revenue was $55, a decrease of -60.43% compared to the previous year's $139. Losses were -$296,471, 125.5% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 24, 2026

Data Sources Report a data error